working towards early retirement
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is everyone pretty much out of Cobi now or still holding?
I agree and soon
nothing to Panic with on this stock - color me confused
SS confirmed this morning
A/S 100MM
Outstanding 20,655,629
Restricted 12,380,844
= Float 8,274,785
thanks Choi
meaning the promoters unloading? or company? hopefully promoter
what do you think this will go to?
TA is gagged on BNPD - be careful
54MM is not high but the A/S on BNPD is 2.5 BILLION and the T/A is gagged. So you have no idea if the 54MM is real or not. PLUS they just had a 5000 :1 Reverse split. So they just reduced everything because they need to dillute again - imo. Be careful. I have been burnt on oil / mineral / gas companies. It takes lots OF $$$$$$$ before the company can really stand on their own feet.
It is supposed to do ok but high float - maybe .09
Ace - we are both in the same boat bud- lost my job recently and need to make some $$ trading. Choi does have some great picks and the king of DD. I got in pspw at .18 and expecting to do be $5 + in a few weeks. COBI and GTGP are real winners also. There are lots of scammers out there - be careful. Choi is the real deal. Good luck to all of us.
CAVR has a N for Reg show Threshold Flag. Doesn't that mean that the shorts are not required to cover?
Subject to the requirements of NASD Rule 3210
Where, for five consecutive settlement days, there are aggregate fails to deliver at a registered clearing agency of 10,000 shares or more and the reported last sale during normal market hours would value the aggregate fail to deliver position at $50,000 or more.
When this occurs, the security becomes subject to mandatory close-out requirements outlined in NASD Rule 3210.
The allowed values are:
•Y = Yes, if the issue is subject to mandatory close-out requirements of Rule 3210.
•N = No, if the issue is NOT subject to mandatory close-out requirements of Rule 3210.
Promo Out by Nebula Stocks today -
COMPASS BIOTECHNOLOGIES (COBI:OB) ANNOUNCES MEMORANDUM OF UNDERSTANDING WITH ARECOR LTD., OF CAMBRIDGE U.K. TO DEVELOP HEAT STABLE HEPATITIS B VACCINE
Compass Biotechnologies Inc. (OTCBB: COBI) is focused on the development and commercialization of generic, biosimilar and bio-better therapeutic products. In continuation of executing on its business plan, the Company is pleased to announce an agreement to develop a heat stable Hepatitis B vaccine formulation based upon acquiring a worldwide exclusive license from ARECOR Ltd. (Cambridge U.K.), using its proprietary Arestatâ„¢ formulation technology.
Globally Hepatitis B virus (HBV) causes about 4 million new infections per year. Of the over 350 million chronic carriers of HBV worldwide, 25% are expected to die withinthe next 5 to 25 years because of liver disease complications caused by the HBV infection. In the USA more than 620,000 will die from Hepatitis B liver-related disease within this same period.
The market for current prophylactic vaccines against hepatitis B is estimated at $800 million, while the global 2010 travel vaccines market was estimated to be worth $2.7 billion. By 2017, the travel vaccines market is estimated to reach $6.6 billion, indicating a CAGR of 13%. None of these vaccines are heat stable and if improperly stored they can lose their effectiveness in a short period of time.
According to the World Health Organization (WHO), global immunization against Hepatitis B is estimated at only 60%. Areas with high rates of infection such as S.E. Asia have coverage of only 28%, while Africa has 49% and the Americas 89%. One of the main constraints in achieving higher immunization targets is maintaining proper refrigeration of the vaccine product. The use of a heat stable Hepatitis B vaccine has the potential to increase the availability and the immunization coverage. Also this strategy may avoid problems with freezing, noted to be one of the primary cold chain problems threatening vaccine integrity.
Currently most protein based drugs need to be kept refrigerated in order to ensure their stability and effectiveness. Arestatâ„¢ is a formulation technology that stabilizes proteins to prevent the loss of their biological activity when stored under non refrigerated conditions.The development of a heat stable Hepatitis B vaccine able to be stored at room temperatures will create a large market opportunity and expand the use of this vaccine not only in the developed markets but in those markets where keeping a vaccine under refrigeration is impossible.
Studies with the Arestatâ„¢ heat stable formulation of Hepatitis B vaccine have demonstrated:
greater than 70% potency being retained after 12 months of storage at 37°C (98.6°F).
that the Arestatâ„¢ heat stable vaccine proved to be just as effective after the 12 months storage at 37°C (98.6° F) when compared to itbeing stored at refrigeration temperatures.
In contrast, a commercially available Hepatitis B vaccine completely lost its effectiveness and showed a 100-fold drop in the anti-hepatitis B titer when stored at 37°C. (98.6° F)
"Arecor has successfully applied Arestatâ„¢ to a wide number of therapeutic proteins and vaccines to minimize degradation in storage.Arestatâ„¢ provides enormous benefit to patients in both developed and developing countries by providing assurance of potency despite potential mishandling or lack of refrigeration," said Thomas Saylor, CEO of Arecor Limited.
Dr. Joseph Sinkule, a Director and Co-Founderof Compass Biotechnologies, agreed, saying, "Current Hepatitis B vaccines require refrigeration and a cold chain to maintain stability and viability, yet freezing must also be avoided.Transportation, storage, and delivery to the end user require an intact cold chain, which is difficult and exceedingly costly to maintain.Successful development of heat stable vaccine products will simplify vaccine storage and delivery, reduce waste, and improve vaccine availability."
"We are very pleased to be partners with ARECOR and will proceed immediately to complete a definitive licensing agreement for this important product," commented Mr. Garth Likes, CEO of Compass Biotechnologies. He went on to say, "C-Pharma, our wholly-owned subsidiary company, will be responsible for development of the heat stable hepatitis B vaccineas the product lies within our ongoing strategy to develop a comprehensive Hepatitis franchise. We will obviously look at other heat stable formulations for products within Compass as well."
About Compass Biotechnologies Compass Biotechnologies (COBI: OB) is anEdmontonbased biotechnology company focused on generic, biosimilar and bio-better product development. From a development perspective, these types of products have lower development costs and lower development risk due to well-established mechanisms of action, a known safety profile, with broad clinical indications for physician use. Comparability testing in preclinical and clinical trials will be needed to show the added benefits of the biosimilar and bio-better drug product.
The Company has recently signed with PanGen Biotech for a manufacturing/supply agreement for development of various biologically-active pharmaceutical ingredients for development of biosimilar and bio-better drug products.Compass has also recently announced a $10 million financing agreement to further our product development programs. The agreement with Arecor will now allow us to differentiate our biosimilar products from others and to commercialize and develop novel, patented bio-better vaccines and drug therapies.
About ARECOR Ltd. Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.Arecor has developed Arestatâ„¢, a patented set of tools for stabilization, to enable the presentation of labile biologicals as stable aqueous formulations even at high concentrations or in situations where cold storage is not practical or desirable. Arestatâ„¢ has shown to successfully address the major pathways of degradation including aggregation, hydrolysis, oxidation and deamidation. As a simple reformulation, Arestatâ„¢ can be readily incorporated into standard manufacturing practice, without covalent modification of the biological and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.
About C-Pharma Compass has a private wholly-owned subsidiary company called C-Pharma Inc. The Company is charged with the creation of a Hepatitis product(s) franchise.C-Pharma acquired the rights to a novel vaccine technology which is currently being developed for Hepatitis C applications. This technology was developed at the National Institutes of Health (NIH) and licensed to the Company on a worldwide exclusive basis.In addition C-Pharma is developing its own generics for two anti-hepatitis drugs known as ribavirin and pegylated alpha interferon.These two drugs are used in patients who are chronically infected with the Hepatitis and in combination are the current standards of care for Hepatitis disease.These two drugs exceed over$2 billiona year in sales worldwide.
Compass Biotechnologies (Cobi:Ob) Announces Memorandum of Understanding With Arecor Ltd., of Cambridge U.K. to Develop Heat Stable Hepatitis B Vaccine
EDMONTON, April 26 /PRNewswire/ - Compass Biotechnologies Inc. (OTCBB: COBI) is focused on the development and commercialization of generic, biosimilar and bio-better therapeutic products. In continuation of executing on its business plan, the Company is pleased to announce an agreement to develop a heat stable Hepatitis B vaccine formulation based upon acquiring a worldwide exclusive license from ARECOR Ltd. (Cambridge U.K.), using its proprietary Arestatâ„¢ formulation technology.
Globally Hepatitis B virus (HBV) causes about 4 million new infections per year. Of the over 350 million chronic carriers of HBV worldwide, 25% are expected to die within the next 5 to 25 years because of liver disease complications caused by the HBV infection. In the USA more than 620,000 will die from Hepatitis B liver-related disease within this same period.
The market for current prophylactic vaccines against hepatitis B is estimated at $800 million, while the global 2010 travel vaccines market was estimated to be worth $2.7 billion. By 2017, the travel vaccines market is estimated to reach $6.6 billion, indicating a CAGR of 13%. None of these vaccines are heat stable and if improperly stored they can lose their effectiveness in a short period of time.
According to the World Health Organization (WHO), global immunization against Hepatitis B is estimated at only 60%. Areas with high rates of infection such as S.E. Asia have coverage of only 28%, while Africa has 49% and the Americas 89%. One of the main constraints in achieving higher immunization targets is maintaining proper refrigeration of the vaccine product. The use of a heat stable Hepatitis B vaccine has the potential to increase the availability and the immunization coverage. Also this strategy may avoid problems with freezing, noted to be one of the primary cold chain problems threatening vaccine integrity.
Currently most protein based drugs need to be kept refrigerated in order to ensure their stability and effectiveness. Arestatâ„¢ is a formulation technology that stabilizes proteins to prevent the loss of their biological activity when stored under non refrigerated conditions. The development of a heat stable Hepatitis B vaccine able to be stored at room temperatures will create a large market opportunity and expand the use of this vaccine not only in the developed markets but in those markets where keeping a vaccine under refrigeration is impossible.
Studies with the Arestatâ„¢ heat stable formulation of Hepatitis B vaccine have demonstrated:
greater than 70% potency being retained after 12 months of storage at 37°C (98.6°F).
that the Arestatâ„¢ heat stable vaccine proved to be just as effective after the 12 months storage at 37°C (98.6° F) when compared to it being stored at refrigeration temperatures.
In contrast, a commercially available Hepatitis B vaccine completely lost its effectiveness and showed a 100-fold drop in the anti-hepatitis B titer when stored at 37°C. (98.6° F)
"Arecor has successfully applied Arestatâ„¢ to a wide number of therapeutic proteins and vaccines to minimize degradation in storage. Arestatâ„¢ provides enormous benefit to patients in both developed and developing countries by providing assurance of potency despite potential mishandling or lack of refrigeration," said Thomas Saylor, CEO of Arecor Limited.
Dr. Joseph Sinkule, a Director and Co-Founder of Compass Biotechnologies, agreed, saying, "Current Hepatitis B vaccines require refrigeration and a cold chain to maintain stability and viability, yet freezing must also be avoided. Transportation, storage, and delivery to the end user require an intact cold chain, which is difficult and exceedingly costly to maintain. Successful development of heat stable vaccine products will simplify vaccine storage and delivery, reduce waste, and improve vaccine availability."
"We are very pleased to be partners with ARECOR and will proceed immediately to complete a definitive licensing agreement for this important product," commented Mr. Garth Likes, CEO of Compass Biotechnologies. He went on to say, "C-Pharma, our wholly-owned subsidiary company, will be responsible for development of the heat stable hepatitis B vaccine as the product lies within our ongoing strategy to develop a comprehensive Hepatitis franchise. We will obviously look at other heat stable formulations for products within Compass as well."
About Compass Biotechnologies
Compass Biotechnologies (COBI: OB) is an Edmonton based biotechnology company focused on generic, biosimilar and bio-better product development. From a development perspective, these types of products have lower development costs and lower development risk due to well-established mechanisms of action, a known safety profile, with broad clinical indications for physician use. Comparability testing in preclinical and clinical trials will be needed to show the added benefits of the biosimilar and bio-better drug product.
The Company has recently signed with PanGen Biotech for a manufacturing/supply agreement for development of various biologically-active pharmaceutical ingredients for development of biosimilar and bio-better drug products. Compass has also recently announced a $10 million financing agreement to further our product development programs. The agreement with Arecor will now allow us to differentiate our biosimilar products from others and to commercialize and develop novel, patented bio-better vaccines and drug therapies.
About ARECOR Ltd.
Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics. Arecor has developed Arestatâ„¢, a patented set of tools for stabilization, to enable the presentation of labile biologicals as stable aqueous formulations even at high concentrations or in situations where cold storage is not practical or desirable. Arestatâ„¢ has shown to successfully address the major pathways of degradation including aggregation, hydrolysis, oxidation and deamidation. As a simple reformulation, Arestatâ„¢ can be readily incorporated into standard manufacturing practice, without covalent modification of the biological and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.
About C-Pharma
Compass has a private wholly-owned subsidiary company called C-Pharma Inc. The Company is charged with the creation of a Hepatitis product(s) franchise. C-Pharma acquired the rights to a novel vaccine technology which is currently being developed for Hepatitis C applications. This technology was developed at the National Institutes of Health (NIH) and licensed to the Company on a worldwide exclusive basis. In addition C-Pharma is developing its own generics for two anti-hepatitis drugs known as ribavirin and pegylated alpha interferon. These two drugs are used in patients who are chronically infected with the Hepatitis and in combination are the current standards of care for Hepatitis disease. These two drugs exceed over $2 billion a year in sales worldwide.
The Company’s near-term plans are to submit market applications in multiple countries for Compass’s generic, biosimiliar and bio better products as well as to complete C-Pharma’s antiviral generic drugs and to complete Phase I safety, immunology & efficacy studies of the HCV vaccine in humans. The two Companies together will create value by achieving major developmental milestones, by generating revenue from the sales of drug products and obtaining proof in humans that VLP vaccine immunization leads to development of neutralizing antibodies that attack the HCV virus and prevent infection.
The Company will continue to advance the development of other anti-viral pipeline products and we plan to begin Phase I safety studies of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection. An antibody product derived from healthy volunteers administered VLP vaccine inoculations will be evaluated as a passive immunotherapy product in patients undergoing liver transplantation to prevent or significantly delay the liver graft re-infection by the hepatitis C virus.
It is not our intent to compete directly with the major drug companies. Rather, we are a product development company focusing on strategic alliances, joint ventures and other strategies to execute the required pre-clinical, early stage clinical stage trials to get generic, biosimiliar and bio-better drug products licensed out to our distribution and commercialization partners. Examples of potential partners might be:
Generic drug company Sandoz, a business unit of Swiss innovator Novartis, has already taken the lead with three follow-on biologics approved in Europe — Omnitrope, Binocrit and Zarzio. Sandoz also offers the only biosimiliar on the US market. Approval of Omnitrope was possible, according to the US Food and Drug Administration (FDA), because the drug is relatively simple, well characterized and shown to be highly similar to Pfizer’s branded drug Genotropin.
Teva Pharmaceuticals, a leading generics producer, also intends to become a major player in biosimilars. It has one product on the European market (Tevagrastim) and has improved its biologics capabilities through the recent acquisitions of Barr Pharmaceuticals and CoGenesys, both US. More recently, Israel-based Teva formed a strategic partnership with Swiss custom manufacturer Lonza to jointly develop, manufacture and market biosimilars.
Other generics companies are expected to enter Western markets in the near future. For example, Indian manufacturers such as Ranbaxy, Dr. Reddy’s Laboratories and Biocon, which market products in India, hope eventually to gain approvals in Europe and, ultimately, the US.
Several large pharmaceutical innovators have also indicated interest. US-based Eli Lilly, having completed the $6.5bn acquisition of compatriot ImClone Systems, has launched an initiative to develop follow-on biologics. The UK’s AstraZeneca is also considering participating in the biosimilars market.
The most proactive major pharma company, however, appears to be US-based Merck & Co, which recently established Merck BioVentures (MBV) and agreed to purchase a portfolio of follow-on biologics candidates and commercial manufacturing facilities from US-based Insmed, a developer of follow-on biologics and biopharmaceuticals.
The leading biobetter companies are Novo Nordisk and Merck & Co, Amgen, Biogen Idec, Eli Lilly, Roche and Sanofi-aventis, as well as the large pharmaceutical companies AstraZeneca, GlaxoSmithKline, Novartis and Pfizer.
COBI Security Details
Share Structure
Market Value1 $2,062,969 a/o Apr 25, 2011
Shares Outstanding 14,949,053 a/o Dec 17, 2010
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment
.30 is good before news
someone prob knows about news coming and loading up
Looks like Promo going http://ow.ly/528bs
gapper in the morning for sure
cool - thanks
Sorry if I missed it - Is Ramo a new pick?
cool thank you
Thks - I realize no one really knows exact date but in your opinion would soon = 1 - 3 months or soon = 1 - 3 weeks? TIA
Does anyone have any idea appox timing of news or filings? Just reading all of your DD here and looks pretty good.
Cool - thanks Choi
Are we expecting any MoMo or news to bring this to $2. soon?
Good News - $1 land here we come
Don't get me wrong - all of the picks are solid. I just think that some just jump out of one and jump into the next when there are several plays announced too close together. The good thing is that even if they do go down temporarily - they will come back up because they are solid.
But some people get in one and when it goes down they freak and sell because they do not understand what they own. Then they lose money and have bad feelings and cause others to freak and sell. Just the penny stock mentality.
Sure they could get in at .18 and sell at .30 67% gain
I think some said that they did
well both look like solid plays but that is what happens when you have too many plays being announced close together. Seen it too many times.
I agree - that play will probably dip a little anyway. COBI is a solid play.
looks like people leaving and going into the next play
Are people selling COBI to get the new pick?
gaps are the difference between the close of one day and the open of another day. Ex close today at.90 and open up tomorrow at 1.20. Many times MM's will bring the pps down to fill those gaps. Didn't believe it at first - but have watched it happen too many times.
plus there are some gaps in the .30's I am sure some MM's want to fill. I hope I am wrong but it would definitely create a buying frenzy. I know I will be there if it happens.
MNYC - why you think it will go to .50 soon - plan on shorting it a bit more?
Can't wait to go to NASDQ in very near future
Who are you kidding - You are the one Shorting. THat is the reason it has gone down so much. This is a Rock Solid Stock.
In the first first two picks - long & Strong. Think someone is shorting the first pick tho - but all good
Thanks Choi - this looks great and pspw will get back on track soon too.
Lack of volume is key here. Could be from the 8K coming out late on Friday and many did not look at it until today when PR came out. I think the rest of the week - will give people time to see how undervalued this really is and the volume will come in and pps goes WAY UP imo